Advancements in Breast Biopsy Devices: Improving Breast Cancer Diagnosis

 The major factors driving the growth of Breast Biopsy Devices Market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and non-invasive procedures, and the improved reimbursement scenario.

What the Market Looks Like?

Breast Biopsy Devices Market  is projected to reach USD 2.6 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 10.0% from 2023 to 2028.

Download  PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805

Market Segmentation: -

Based on the type, the global breast biopsy devices market is segmented into biopsy needles, guidance systems, localization wires, assay kits, liquid biopsy instruments, biopsy tables, and other devices. The assay kits segment is expected to grow at the highest CAGR during the forecast period.

Based on the procedure, the breast biopsy devices market is segmented into needle open surgical breast biopsy, breast biopsy, and liquid breast. The liquid breast biopsy segment is anticipated to register the highest growth rate over the forecast period.

Based on application, the market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening accounted for the largest share of the market in 2022. However, the therapy selection segment is expected to grow at the highest CAGR during the forecast period.

Based on the end user, the breast biopsy devices market is segmented into hospitals & surgical centers, breast care centers, and imaging clinics & diagnostic centers. The hospitals & surgical centers segment accounts for the largest share of the market in 2022.

What Drives the Market?

The growth of the global market for Breast Biopsy is primarily influenced by the following factors:

1 Growing incidence of breast cancer
2 Increasing number of breast cancer screening programs
3 Increasing demand for minimally invasive and non-invasive procedures
4 Growing awareness regarding early detection of breast cancer
5 Improved reimbursement scenario.

Regional Analysis: -

The North American breast biopsy devices market is estimated to grow significantly from 2023 to 2028. factors such as ongoing technological advancements, rising breast cancer incidence rates, favorable reimbursement scenarios, and new breast density notification laws drive market growth in North America. This region has a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.

Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189011805

Recent Developments:

• Hologic, Inc, an innovative medical technology company primarily focused on improving women’s health, announced today that it has completed the purchase of SOMATEX Medical Technologies GmbH; the deal size is $64 million.
• In 2022 Danaher Corporation launched Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System, the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems.
• Argon Medical Devices announced the launch of the SuperCore advantage semi-automatic biopsy instrument’s newest addition to its soft tissue biopsy product portfolio in the united states. The next-generation soft tissue biopsy instrument provides a superior volume of tissue samples. Collecting more tissue volume may increase the likelihood of an accurate diagnosis.

Top Key Players: -

As of 2022, prominent players in the breast biopsy devices market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Medtronic (IRL), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL),  Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany) and Exact Sciences Corporation (US).

The breast biopsy devices market is highly competitive, with several key players globally. Market dynamics, such as technological advancements, regulatory changes, and the evolving healthcare landscape, can impact the growth and development of this market.

Image-Guided Radiation Therapy Market worth $2.4 billion by 2028

 The expansion of the image-guided radiation therapy market is propelled by several synergistic factors, including robust healthcare infrastructure, escalating cancer prevalence, conducive reimbursement policies, technological innovations, active research initiatives, well-defined regulatory frameworks, growing minimally invasive procedure adoption, and the presence of key market players in developing regions. This amalgamation of drivers has engendered substantial market growth. Continued technological advancements, heightened emphasis on non-invasive cancer interventions, and a supportive healthcare ecosystem are anticipated to sustain this upward trajectory. Nevertheless, market expansion faces constraints posed by competitive alternatives, including automated radiation therapy systems, intensity modulation radiation therapy (IMRT), and other radiotherapeutic approaches.

The report "Image-Guided Radiation Therapy Market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171554723

Market Segmentation :-

PET/ MRI-guided radiation therapy segment to register a significant growth rate over the forecast period of 2022-2028.

Based on the product, the image-guided radiation therapy market is segmented into LINAC (linear accelerator), 4D gating/ 4D RT, PET/ MRI-guided radiation therapy, CT scanning, and portal imaging. The capability of PET/MRI to furnish functional insights directs the administration of radiation doses, effectively mitigating healthy tissue exposure and subsequently alleviating the occurrence of adverse effects. This contribution significantly bolsters the market trajectory of image-guided radiation therapy, enhancing its appeal and positioning within the healthcare landscape.

The breast cancer application segment accounted for a significant share of the image-guided radiation therapy market in 2022-2028.

Based on the application, the image-guided radiation therapy market is segmented into breast cancer, prostate cancer, head & neck cancer, lung cancer, gastrointestinal cancer, gynecological cancer, and other applications. The rising incidence of cancer worldwide is a significant driver for the image-guided radiation therapy market. The precision inherent in image-guided radiation therapy (IGRT) mitigates the necessity for frequent and discomforting repositioning of patients during treatment sessions.

 

Intensity modulation radiation therapy procedure segment accounted for the largest share of the image-guided radiation therapy market in 2022-2028.

Based on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, stereotactic therapy, proton beam therapy, intensity modulation radiation therapy,  and particle therapy. The intensity modulation radiation therapy procedure segment is estimated to hold the 39.2%  market share of the image-guided radiation therapy market in 2022. Intensity Modulated Radiation Therapy (IMRT) is instrumental in crafting tailored treatment blueprints through the optimization of radiation administration based on tumor dimensions, contours, and placement. This congruence aligns seamlessly with the personalized treatment ethos central to Image-Guided Radiation Therapy (IGRT).

Hospitals segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.

The major end users in the image-guided radiation therapy market are independent radiotherapy centers and hospitals. Hospitals are expected to account for a major market share in 2022. Healthcare institutions grapple with a considerable influx of cancer patients, thereby magnifying the attraction towards image-guided radiation therapy (IGRT). The precision inherent in IGRT's tumor-targeting proficiency and its streamlined treatment delivery harmonize seamlessly with the necessity of proficiently managing the patient caseload.

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=171554723

Regional Analysis:-

In 2022, the North American region is expected to register significant growth in the market during the forecast period. North America comprises the US and Canada. North America has an advanced healthcare infrastructure, which is associated with a higher incidence of cancer. In North America, a highly developed healthcare infrastructure coupled with ready access to state-of-the-art medical technologies creates a conducive environment for the assimilation of progressive treatment modalities, such as image-guided radiation therapy (IGRT).

Key Players:-

As of 2022, prominent players in the image-guided radiation therapy market are Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.

Recent developments

Recent developments, such as Philips' Zenition 10, GE HealthCare's advances in PET/MR capabilities, and the launch of Pixxoscan, highlight the industry's commitment to advancing cancer care.

Conclusion

Image-Guided Radiation Therapy is revolutionizing cancer treatment by offering precise, patient-centric care. As a medical industry expert, I'm thrilled to witness this transformation. With continued advancements, a supportive healthcare ecosystem, and a global focus on non-invasive cancer interventions, IGRT is set to play a pivotal role in shaping the future of cancer treatment worldwide. As the industry embraces innovation, research, and collaboration, the promise of improved cancer outcomes becomes increasingly achievable.

Digital X-ray Market: Technological advancements and product development

 The major factors driving the growth of Digital X-ray Market include the increasing geriatric population and growth in disease incidence as well as favorable government regulations, investments, and initiatives. The advantages of digital X-ray systems have played a key part in their adoption; their speed and accuracy, as well as quick processing times, allow for significantly higher patient screening volumes than earlier. This has pushed companies to focus on product development and innovation.

The global digital X-ray market is expected to reach USD 16.4 billion by 2026 from an estimated USD 11.1 billion in 2021, at a CAGR of 8.1% from 2021 to 2026.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164

Market Segmentation: -

·         Based on technology, the market is segmented into direct radiography and computed radiography. The direct radiography segment commanded the largest share of the global market in 2020.

·         Based on portability, the digital X-ray market is segmented into fixed digital X-ray systems and portable digital X-ray systems. Fixed digital X-ray systems include floor-to-ceiling-mounted systems and ceiling-mounted systems, while portable digital X-ray systems include mobile X-ray systems and handheld X-ray systems.

·         The global digital X-ray systems market is divided into new and retrofit digital X-ray systems. The retrofit digital X-ray systems segment is expected to dominate the market during the forecast period.

·         Based on end users, the X-ray market is segmented into diagnostic centers, hospitals, and dental care centers. Hospitals are expected to dominate the market during the forecast period.

·         Based on applications, the market is segmented into general radiography, dental applications, fluoroscopy, cancer, and mammography applications. The general radiography segment is expected to dominate this market during the forecast period

Regional Analysis: -

The digital X-ray market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for digital X-ray systems, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

Request Sample Pages :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=1164

Recent Developments:-

• In March 2021, Koninklijke Philips N.V. (Netherlands) received US FDA 510(k) clearance for CombiDiagnost R90, a high-end digital radiography-based fluoroscopy system
• In August 2020, GE Healthcare (US) received FDA 510(k) clearance for Pristina Serena Bright, a contrast-enhanced mammography solution for biopsy
• In November 2018, Siemens Healthineers (Germany) introduced Multix Impact, a floor-mounted radiography system, at the Congress of the Radiological Society of North America (RSNA) in Chicago, US

Top Key Players: -

The digital X-ray market is dominated by Siemens Healthineers (Germany), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), FUJIFILM Holdings Corporation (Japan), and Canon, Inc. (Japan). The other leading market players include Carestream Health (US), Shimadzu Corporation (Japan), Hologic Inc. (US), Agfa-Gevaert Group (Belgium), Samsung Medison (South Korea), and Konica Minolta (Japan).

 

Preimplantation Genetic Testing Market Exclusive Report by MarketsandMarkets™

 As per the recently published report by MarketsandMarket™, The report  "Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028", is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period. 

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
 
Browse

• 182     Market Data Tables
• 44       Figures
• 245     Pages and in-depth TOC on "Preimplantation Genetic Testing Market - Global Forecast to 2028”

Some of the prominent key players are:

• Illumina, Inc. (US),
• Thermo Fisher Scientific Inc. (US),
• Agilent Technologies, Inc. (US),
• Revvity (US), 
• The Cooper Companies, Inc. (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Preimplantation Genetic Testing Market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605

• Preimplantation genetic screening, or aneuploidy screening, involves screening embryos for the assessment of aneuploidy. This segment is expected to dominate the global preimplantation genetic testing market during the forecast period, driven by a decrease in female fertility with rising maternal age, better implantation rate and reduced IVF cycle times.
• Based on the products, the global preimplantation genetic testing market is broadly segmented into instruments, reagents & consumables, and software & services. The expanding applications of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders).
• By end user, the global preimplantation genetic testing market is broadly segmented into hospitals, diagnostic labs, fertility clinics, and other end users. The large share of this segment can be attributed to factors such as the increasing number of fertility centers globally, the high success rate of treatment in fertility centers, and growing medical tourism in developing countries.
• Based on the region, the preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American market is driven by high incidence of chromosomal disorders, and an increasing number of awareness programs.

The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in this market is attributed to the increasing demand for assisted reproductive technologies, rising maternal age trends, and ongoing research and development in the field of genetics. On the other hand, socio-ethical concerns surrounding preimplantation genetic testing may challenge the growth of market. Whereas, use of fertility treatment options by single parents and same-sex couples provides growth opportunities for market.

Hollow Fiber Filtration Market: Future Growth in the biopharmaceutical industry

 The growth of the global Hollow Fiber Filtration Market is driven by factors such as the rising preference for continuous manufacturing, increasing use of single use technologies, and the rising biopharmaceutical industry. In addition, emerging economies, and increased investment cell-based research are expected to provide significant growth opportunities for players in the market.

The global Hollow fiber filtration market is projected to reach USD 597 million by 2026 from USD 303 million in 2021, at a CAGR of 14.5% during the forecast period.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267011039

Market Segmentation:

Based on material, the market is segmented into polymeric and ceramic. The polymeric segment is further sub segmented into PS/PES, Polyvinylidene fluoride (PVDF), and Other polymeric materials. In 2020, PS/PES membrane filters accounted for the largest market share as they are designed to eliminate particulates during standard filtration. They have low protein and drug binding characteristics and are stable at alkaline pH. PS/PES membranes are recommended for aqueous applications and for biological samples.

Based on application type, the market is segmented into continuous cell perfusion, harvest and clarification, and concentration and diafiltration. In 2020, continuous cell perfusion accounted for the largest market share due to the advantages of hollow fibers in continuous cell perfusion, such as enabling efficient cell separation (with low shear) and allowing robust large-scale manufacturing.

Regional Analysis:

The Asia Pacific market is projected to witness the highest growth rate during the forecast period, primarily due to innovation, a giant talent pool of scientists, low labor, and manufacturing costs. The region has also witnessed mass production because of technology and a rise in continuous manufacturing instead of batch production in the previous era.

Recent Developments

• In 2020, Sartorius Stedim Biotech (France) acquired WaterSep BioSeparations to expand its product offerings in the market.
• In 2020, Repligen Corporation (US) acquired ARTeSYN Biosolutions. This acquisition helped expand the company’s offerings in the hollow fiber filtration market.
• In 2020, Repligen Corporation (US) acquired Engineered Molding Technology. This acquisition expanded Repligen’s line of single-use filtration products and gave the company more flexibility to scale and expand its single-use systems portfolio in the hollow fiber filtration market.
• In 2020 Danaher (US) acquired the Biopharma business from GE Company’s Life Sciences division. This business is known as Cytiva and acts as a standalone operating company within Danaher’s Life Sciences segment. This acquisition strengthened Danaher’s position in the hollow fiber filtration market.

Request for Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=267011039

Top Key Players:

Prominent players in the Hollow Fiber Filtration Market are Repligen Corporation (US), Danaher (US), Asahi Kasei Corporation (Japan), Parker-Hannifin Corp (US), Sartorius Stedim Biotech S.A (France), TOYOBO CO., LTD (Japan), and Cantel Medical (US). The key players in this market are focusing on strategic expansions, and acquisition to expand their presence in the market.

The hollow fiber filtration market is expected to continue evolving, driven by advancements in technology, changes in industry regulations, and the increasing need for efficient and sustainable filtration solutions. To obtain the most current and detailed information about the market, it is advisable to consult industry reports, market analysts, and industry experts.

 

Electronic Clinical Outcome Assessment (eCOA) Solution Market worth $3.9 billion by 2029

 As per the recently published report by MarketsandMarket™, The report "Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use ([Clinical trial: Onco, Rare, Mental Health], RWE, Registery], End User, and Region - Global Forecast to 2029", is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6%.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87857774
 
Browse

• 150     Market Data Tables
• 45       Figures
• 211     Pages and in-depth TOC on "Electronic Clinical Outcome Assessment (eCOA) Solution Market - Global Forecast to 2029”

Some of the prominent key players are:

• Signant Health (US),
• IQVIA HOLDINGS INC, (US),
• Oracle Corporation (US),
• Kayentis (France),
• TransPerfect (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Electronic Clinical Outcome Assessment (eCOA) Solution Market.

 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=87857774

• Based on component, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into software, services, and wearable, mobile & other devices. The wearable, mobile & other devices segment is further categorized into bring your own device model (BYOD), Provisioned device model, and hybrid model. The hybrid model is the fastest growing in Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to its ability to offer a balanced and flexible approach to data collection in clinical trials.
• Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. Among these the observational studies and real-world evidence generation is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to an increasing emphasis on real-world data's significance in healthcare decision-making.
• Based on end users, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), medtech companies, government organizations, research centers & academic institutes, hospitals & healthcare providers, and consulting service companies.
• The Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America accounted for the largest share of the Electronic Clinical Outcome Assessment (eCOA) Solutions market.

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth of the eCOA solution market is mainly driven by increasing investment in R&D by medical device companies, and rising penetration of connected devices in healthcare institutes.

Insulin Delivery Devices Market worth $46.2 billion by 2028

 Diabetes is a chronic medical condition affecting millions of lives worldwide. Managing diabetes requires a delicate balance of monitoring blood sugar levels and administering insulin as needed. Insulin delivery devices have emerged as crucial tools in this endeavor, revolutionizing the way individuals with diabetes manage their condition.

The report Insulin Delivery Devices Market is expected to grow at a CAGR of 8.5% from USD 30.8 Billion in 2023 to USD 46.2 billion in 2028.

 

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092

Market Segmentation:

Segments of the devices taken into consideration in the insulin delivery device market include insulin pens, insulin pumps, insulin syringes, and pen needles. The insulin subsegment includes reusable pens and disposable pens. The market for reusable insulin pens is anticipated to continue to grow at the highest CAGR during the forecast period.

The end users in the insulin delivery device market are hospitals &clinics and patients/homecare. The patients/homecare segment is anticipated to grow at the highest CAGR during the forecast period.

 

Regional Analysis: -

North America, followed by Europe, held the largest market share in 2022. The market for insulin delivery device in North America was further dominated by the US.

Recent Developments of Insulin Delivery Devices Industry

• In 2023, Embecta Corp. opened a new global headquarters office at 300 Kimball Drive, Suite 300, IN Parsippany, N.J. The site is expected to be home to members of the leadership team, global support functions and North American commercial organization to develop and provide solutions that make life better for people coping with diabetes.
• In 2023, Eli Lilly announced price reductions of 70% for its most prescribed insulins and an expansion of its Insulin Value Program that caps patients out-of-pocket cost at USD 35 or less per month.
• In 2023, Novo Nordisk launched the first smart insulin pens NovoPen 6 and NovoPen Echo Plus available in the UK.
• In 2022, Medtronic entered into a set of definitive agreements to acquire EOFlow Co. Ltd., a manufacturer of the EOPatch device- a tubeless, wearable and fully disposable insulin delivery device.

 

Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092

Top Key Players: -

The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formely Becton, Dickinson and Company Diabetes Care Business (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

 

Insulin delivery devices are changing the landscape of diabetes management by addressing the challenges that individuals with diabetes face on a daily basis. These devices offer precision, convenience, and improved quality of life, enhancing patient adherence and reducing the risk of complications. As technology continues to advance, we can expect even more innovative solutions that empower individuals to take control of their diabetes and lead healthier, more fulfilling lives.

 

Unlocking the Potential: HLA Typing Market's Astonishing Growth

 As per the recently published report by MarketsandMarkets™, The report "HLA Typing Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) & Region - Global Forecast to 2028", is projected to reach USD 2.1 billion by 2028 from an estimated value of USD 1.4 billion in 2022, at a CAGR of 6.5% during the forecast period.

 
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877
 
Browse

• 180     Market Data Tables
• 37       Figures
• 223     Pages and in-depth TOC on " HLA Typing Market - Global Forecast to 2028”

Some of the prominent key players are:

• Bio-Rad Laboratories, Inc. (US),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• QIAGEN N.V. (Netherlands),
• Thermo Fisher Scientific Inc. (US), 
• bioMérieux S.A. (France) and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the HLA Typing Market.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877

• Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022.
• Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.
• Based on application, the diagnostic applications market is segmented into donor-recipient match, Cancer Diagnosis and prevention, Infectious and non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period.
• Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of the HLA Typing Market.

Recent Developments:

• In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System
• In August 2022 Roche developed a new digital Light cycler system that helps determine a patient’s cancer.
• In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.

The HLA Typing industry's evolution is an exciting journey, with advancements in technology and increasing awareness of the vital role it plays in diagnostics and transplant medicine. This market's growth is not just a statistic; it represents the potential to improve patient care and save lives, making it an integral part of the healthcare landscape. Stay tuned for more updates as we continue to track the growth and development of this dynamic industry.